secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0000950170-23-023753
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology acquires Apexigen in ~$16M all-stock deal; CMO resigns
---------------------------------------------------------------------

- Merger valued at ~$16M enterprise value; implied $0.64 per Apexigen share; exchange ratio 0.1725 PYXS shares per APGN share.
- Pyxis stockholders to own ~90% of combined company; Apexigen stockholders ~10%; deal expected to close mid-2023.
- Adds klinical-stage CD40 agonist sotigalimab (Phase 2) and APXiMAB antibody platform to Pyxis' FACT ADC toolkit.
- Cash runway extended into first half of 2025 per company guidance.
- CMO Jay Feingold steps down effective June 15, 2023; will serve as advisor until successor is named.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/0000950170-23-023753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/pyxs-20230523.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-023753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer